14-Dec-2020 - Boehringer Ingelheim GmbH

Boehringer Ingelheim to acquire NBE-Therapeutics

Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC platform.  NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors.  Importantly, Boehringer Ingelheim gains access to an innovative and unique platform that it will use to build a leading ADC portfolio and develop potential combinations with other assets from its cancer immunology portfolio.

“NBE-Therapeutics’ iADC platform adds exceptional tumor targeting capabilities to our oncology portfolio. Together with our immune cell-targeting assets, this could enable new powerful combinations that will allow for efficacious and durable treatments for patients,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “This acquisition is a further example of Boehringer Ingelheim’s long-term strategy to enhance our position as an innovator of novel cancer therapies for patients in need. We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work.” 

The total transaction value is 1.18 billion euros and also includes contingent clinical and regulatory milestones. 

“I am extremely proud of the NBE-Therapeutics’ team and delighted that our world class ADC expertise is being recognized by Boehringer Ingelheim.  This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics. “We look forward to progressing NBE-002, our lead program and best-in-class anti ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities.” 

Boehringer Ingelheim’s cancer cell directed research is focused on the development of targeted therapies for the treatment of difficult-to-treat solid tumors.  Inducing tumor cell death is a key component, and ADC based approaches have emerged as a powerful targeted therapy with potential for induction of immunogenic cell death at reduced systemic exposure and toxicity.  

The NBE-Therapeutics’ acquisition will significantly strengthen Boehringer Ingelheim’s strategic focus on targeted cancer cell-directed therapies and complements existing capabilities in antigen discovery as well as antibody and T-cell engager technologies. By combining its world-class, in-house research and development with that of highly innovative biotechnology companies, Boehringer Ingelheim is developing innovative therapies and accelerating the delivery of the next generation of cancer treatments. This builds on recent strategic acquisitions and collaborations, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are also contributing assets. 

NBE-Therapeutics is headquartered in Basel, Switzerland, where it was founded with financial backing from a syndicate of both corporate and institutional investors, including the Boehringer Ingelheim Venture Fund, and PPF Group, as their largest shareholders, and Denmark’s Novo Holdings. NBE-Therapeutics’ technology platform and derived assets are protected by a broad portfolio of patents and licenses.

The consummation of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021.

Facts, background information, dossiers
  • Boehringer Ingelheim
  • acquisitions
  • antibody drug conju…
More about Boehringer Ingelheim
  • News

    Boehringer Ingelheim and Google Partner for Pharma R&D

    Boehringer Ingelheim announced a collaborative agreement with Google Quantum AI, focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. The new partnership ... more

    New SARS-CoV-2 neutralizing antibody enters clinical phase

    Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF’s exper ... more

    Boehringer Ingelheim acquires swiss biotech start-up

    Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first in class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is cur ... more

  • Companies

    Boehringer Ingelheim GmbH

    The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed f ... more

    Boehringer Ingelheim microParts GmbH

    Innovative drugs for humans and animals - the research-based pharmaceutical company Boehringer Ingelheim has stood for more than 130 years. Boehringer Ingelheim is one of the 20 leading companies in the industry and is still a family business. For the three divisions Human Pharmaceuticals, ... more

    Boehringer Ingelheim España, S.A.

    Contribute value through innovation: the company has followed this principle in all its activities for generations. The aim of Boehringer Ingelheim is to act with long-term responsibility and based on its values. The corporate responsibility of Boehringer Ingelheim is guided by the fundamen ... more

More about NBE-Therapeutics
  • Companies

    NBE-Therapeutics LLC

    NBE Therapeutics was founded in 2012 by Dr. Ulf Grawunder, a seasoned biotech entrepreneur and former CEO/CSO of 4-Antibody, Switzerland, that was recently sold to U.S.-based Agenus (AGEN). Ulf Grawunder, CEO of NBE-Therapeutics, is an expert in the field of fully human therapeutic antibody ... more